Global market valuation was derived through revenue mapping and genetic testing procedure volume analysis across diagnostic, preventive, and wellness application segments. The methodology included:
The identification of over 50 significant manufacturers and service providers in North America, Europe, Asia-Pacific, and Latin America, including molecular diagnostic companies (Myriad Genetics, Labcorp), NGS platform vendors (Illumina, Thermo Fisher Scientific), and bioinformatics providers
Product mapping across NIPT, carrier screening, pharmacogenomic testing, karyotype analysis, thrombophilia testing, Septin 9 biomarker testing, and comprehensive NGS-based applications
Analysis of reported and modeled annual revenues specific to human genetics portfolios, including instrument sales, consumables, and testing services revenue
Coverage of manufacturers and service providers representing 70-75% of global market share in 2024
Extrapolation using bottom-up (test volume × average selling price by country/region, segmented by test type and clinical indication) and top-down (manufacturer revenue validation and bioinformatics services quantification) approaches to derive segment-specific valuations for diagnostic & treatment, preventive medicine, and wellness & e-commerce applications
Cross-validation against national genomic medicine spending data, insurance claims databases for genetic testing procedures, and direct-to-consumer genetic testing market tracking